Health

Wegovy Shows Promise in Treating Serious Liver Disease

Published MAY 2 2025

Story

Above: Wegovy (semaglutide), a Novo Nordisk drug being trialed for treating MASH, on Oct. 16, 2024. Image credit: James Manning/PA Images via Getty Images

The Spin

Narrative A

This breakthrough offers hope for millions of people suffering from a disease with limited treatment options. By addressing both liver inflammation and scarring while tackling the underlying metabolic issues, semaglutide could prevent MASH from progressing to life-threatening conditions like cirrhosis and liver cancer. If approved by the FDA, it would change the treatment paradigm for MASH and possibly save countless lives.

PR Newswire King's College London

Narrative B

While the results appear promising, important questions remain about the drug’s long-term effectiveness, how doctors would measure success, and how long patients would have to be treated. This is significant because MASH can be a lifelong condition, and these medications are not cheap. This is worth considering, as the improvements among those taking the placebo suggest lifestyle changes alone could help many patients.

Science News